Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Recruiting now Phase 2/3 NCT07100080
Run by Bristol-Myers Squibb · for 18 and older · All sexes
What this study is about
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Who can join (things the study team will check)
✅ You may be able to join if…
- Non-squamous NSCLC, not amenable to treatment in curative intent.
- Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation).
- Progressive disease on a 3rd-generation (such as osimertinib, furmonertinib, lazertinib,...) EGFR-TKI-based mono- or combination therapy regimen as the most recent line of therapy in an adjuvant, locally advanced, or metastatic treatment setting.
- Eligible to receive a platinum-based doublet chemotherapy regimen (either cisplatin or carboplatin in combination with pemetrexed).
🚫 You may not be able to join if…
- Inadequate organ function and/or bone marrow reserve.
- Leptomeningeal metastases or spinal cord compression.
- Poorly controlled systemic medical conditions.
- Other protocol-defined inclusion/exclusion criteria apply.
Where this trial is running
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care building, Irvine, California, United States
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange, California, United States
- Shaw Cancer Center, Edwards, Colorado, United States
- Local Institution - 0085, Gainesville, Florida, United States
- Local Institution - 0142, Pembroke Pines, Florida, United States
- Piedmont Healthcare, Atlanta, Georgia, United States
- John B Amos Cancer Center, Columbus, Georgia, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Renown Regional Medical Center, Reno, Nevada, United States
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola, New York, United States
+ 174 more sites.
Who to contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07100080.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.